CY1108919T1 - Θεραπευτικη αγωγη νεφροκυτταρικου καρκινωματος - Google Patents

Θεραπευτικη αγωγη νεφροκυτταρικου καρκινωματος

Info

Publication number
CY1108919T1
CY1108919T1 CY20091100350T CY091100350T CY1108919T1 CY 1108919 T1 CY1108919 T1 CY 1108919T1 CY 20091100350 T CY20091100350 T CY 20091100350T CY 091100350 T CY091100350 T CY 091100350T CY 1108919 T1 CY1108919 T1 CY 1108919T1
Authority
CY
Cyprus
Prior art keywords
therapeutic treatment
cellular cancer
renal cellular
effective amount
therapeutically effective
Prior art date
Application number
CY20091100350T
Other languages
English (en)
Inventor
Esther Helen Rose
Mary Ellen Rybak
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of CY1108919T1 publication Critical patent/CY1108919T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Αποκαλύπτονται μέθοδοι για θεραπεία ασθενών που είναι παρθένοι στη θεραπευτική αγωγή καθώς επίσης ασθενών που έζησαν μια εμπειρία θεραπευτικής αγωγής οι οποίοι έχουν RCC για επίτευξη τουλάχιστο μιας μερικής απόκρισης όγκων οι οποίες συνεπάγονται χορήγηση μιας θεραπευτικά αποτελεσματικής ποσότητας πεγκυλιωμένης ιντερφερόνης άλφα-2b ως μονοθεραπεία ή σε συνδυασμό με μια θεραπευτικά αποτελεσματικής ποσότητας IL-2.
CY20091100350T 1999-04-08 2009-03-24 Θεραπευτικη αγωγη νεφροκυτταρικου καρκινωματος CY1108919T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28835999A 1999-04-08 1999-04-08
EP05002952A EP1535623B1 (en) 1999-04-08 2000-04-06 Renal cell carcinoma treatment

Publications (1)

Publication Number Publication Date
CY1108919T1 true CY1108919T1 (el) 2014-07-02

Family

ID=23106761

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100350T CY1108919T1 (el) 1999-04-08 2009-03-24 Θεραπευτικη αγωγη νεφροκυτταρικου καρκινωματος

Country Status (24)

Country Link
EP (2) EP1535623B1 (el)
JP (2) JP3712914B2 (el)
CN (1) CN1367702A (el)
AR (1) AR029160A1 (el)
AT (2) ATE419002T1 (el)
AU (2) AU777406B2 (el)
BR (1) BR0009644A (el)
CA (1) CA2303752A1 (el)
CO (1) CO5170412A1 (el)
CY (1) CY1108919T1 (el)
DE (2) DE60041291D1 (el)
DK (2) DK1043025T3 (el)
ES (2) ES2239953T3 (el)
HK (2) HK1032533A1 (el)
HU (1) HU230271B1 (el)
MX (1) MXPA00003401A (el)
MY (1) MY155221A (el)
NO (1) NO328983B1 (el)
NZ (1) NZ514629A (el)
PE (1) PE20010026A1 (el)
PT (2) PT1043025E (el)
TW (2) TW200526243A (el)
WO (1) WO2000061174A2 (el)
ZA (1) ZA200108169B (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1043025T3 (da) * 1999-04-08 2005-07-04 Schering Corp Behandling af nyrecellekarcinom
CA2648077A1 (en) * 2006-03-31 2007-11-08 Schering Corporation Parenteral low dose type 1 interferons for bladder cancer
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8053430B2 (en) 2008-10-06 2011-11-08 Haraldsson Boerje Treatment of renal cell carcinoma
JP2013523726A (ja) 2010-04-01 2013-06-17 オンコレナ エービー 腎細胞癌の改良された治療
CN103463623B (zh) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法
WO2018215936A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
PT1066059E (pt) * 1998-03-26 2005-10-31 Schering Corp Formulacoes para proteccao de conjugados de peg-interferao alfa
DK1043025T3 (da) * 1999-04-08 2005-07-04 Schering Corp Behandling af nyrecellekarcinom

Also Published As

Publication number Publication date
DK1535623T3 (da) 2009-04-27
AU2004242454B2 (en) 2007-02-15
TWI310314B (en) 2009-06-01
EP1043025A2 (en) 2000-10-11
CO5170412A1 (es) 2002-06-27
HUP0200781A2 (en) 2002-08-28
JP2001288110A (ja) 2001-10-16
NO328983B1 (no) 2010-07-05
DE60041291D1 (de) 2009-02-12
AU777406B2 (en) 2004-10-14
PE20010026A1 (es) 2001-02-05
WO2000061174A3 (en) 2001-01-25
AU2004242454A1 (en) 2005-01-20
AU4204400A (en) 2000-11-14
BR0009644A (pt) 2002-01-08
DK1043025T3 (da) 2005-07-04
JP2000319196A (ja) 2000-11-21
DE60020442D1 (de) 2005-07-07
HU230271B1 (hu) 2015-11-30
NO20014851L (no) 2001-12-07
DE60020442T2 (de) 2006-05-04
HUP0200781A3 (en) 2002-09-30
CA2303752A1 (en) 2000-10-08
CN1367702A (zh) 2002-09-04
MXPA00003401A (es) 2002-03-08
EP1043025B1 (en) 2005-06-01
HK1032533A1 (en) 2001-07-27
ZA200108169B (en) 2003-01-06
JP3712914B2 (ja) 2005-11-02
AR029160A1 (es) 2003-06-18
HK1075417A1 (en) 2005-12-16
PT1043025E (pt) 2005-09-30
NZ514629A (en) 2004-02-27
EP1043025A3 (en) 2000-12-20
ES2319777T3 (es) 2009-05-12
JP4721488B2 (ja) 2011-07-13
EP1535623B1 (en) 2008-12-31
TW200526243A (en) 2005-08-16
MY155221A (en) 2015-09-30
ATE296638T1 (de) 2005-06-15
EP1535623A1 (en) 2005-06-01
NO20014851D0 (no) 2001-10-05
ES2239953T3 (es) 2005-10-16
WO2000061174A2 (en) 2000-10-19
PT1535623E (pt) 2009-03-19
ATE419002T1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
CY1108919T1 (el) Θεραπευτικη αγωγη νεφροκυτταρικου καρκινωματος
CY1121113T1 (el) Θεραπεια της νοσου ρομρε
TR200200717T2 (tr) Terapötik kinazolin türevleri.
ATE373679T1 (de) Antimikrobiell wirksames oder endotoxin neutralisierendes polypeptid
CY1115782T1 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
EA200100954A1 (ru) Производные камптотецина, обладающие противоопухолевой активностью
DE50002293D1 (de) Verwendung von csf-1-inhibitoren
ES2153862T3 (es) Bisulfan de administracion parenteral para el tratamiento de enfermedades malignas.
BR0112038A (pt) Triazolopirimidinas substituìdas como agentes anticâncer
CY2008007I2 (el) Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου
DE60029944D1 (de) Polyamine und ihre therapeutische verwendung
DK0933995T3 (da) Fremgangsmåde til behandling af endotelskader
HRP20080598T3 (en) Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
EA200300544A1 (ru) Эффективные противоопухолевые лекарственные средства
PT950057E (pt) Enantiomeros de 3-piridilo e sua utilizacao como analgesicos
DE60039730D1 (de) Genetisch manipulierte Herpesviren zur Behandlung von Tumoren
ATE413183T1 (de) Verwendung von laminarin in der behandlung von krebs
NO20003313L (no) Terapeutiske midler
DK1140103T3 (da) Ponazuril til behandling af neurologiske og abortfremkaldende sygdomme forårsaget af Coccidia
DK0588873T3 (da) Behandling af levercancer
TR199802200A2 (xx) S�lfonamid s�bstit�e edilmi� benzopiran t�revleri, �retilme y�ntemi.
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
IT1317731B1 (it) Tassani semisintetici con attivita' antitumorale ed antiangiogenetica.
CY1108922T1 (el) Θεραπεια μελανωματος
EA200201154A1 (ru) Бис(n,n'-бис(2-галоэтил)амино)фосфороамидаты в качестве противоопухолевых агентов